{
  "docId": "019de074-704c-735b-b7a3-613838aa1bf3",
  "docSlug": "9b81d8a09c69afc3f139dc970effabde",
  "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Aeglea BioTherapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 6,
  "pageCount": 39,
  "prevPage": 5,
  "nextPage": 7,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 3,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-704c-735b-b7a3-613838aa1bf3/6",
  "deckHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3",
  "deckJsonHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3.json",
  "deckAnchorHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3#slide-6",
  "components": [
    {
      "bbox": {
        "h": 0.18,
        "w": 0.88,
        "x": 0.06,
        "y": 0.45
      },
      "kind": "list",
      "text": "Pegzilarginase in Arginase 1 Deficiency: MAA under review with EMA, potential decision on approval in late 2023; Continuing to engage with FDA to identify potential path to BLA resubmission",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "173908dc-b11d-4ea6-a0eb-00526922d13d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.88,
        "x": 0.06,
        "y": 0.18
      },
      "kind": "list",
      "text": "Pegtarviliase in Homocystinuria: Fast Track Designation received from FDA; Currently dosing in cohort 3 at 1.35 mg/kg once weekly in Phase 1/2 clinical trial",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "38ed1146-ff75-4d49-8e3a-165309ec537c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.88,
        "x": 0.06,
        "y": 0.68
      },
      "kind": "list",
      "text": "Corporate: Jeff Goldberg appointed CEO in November 2022; $57.3 million in cash and available funds as of December 31, 2022; projected runway into fourth quarter of 2023",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d4f8a378-33d1-4227-a0bf-a288121f53e2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.35,
        "x": 0.068,
        "y": 0.915
      },
      "kind": "source-note",
      "text": "1 Includes cash, cash equivalents, marketable securities, and restricted cash",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "861c985a-1c6e-4e5f-89d9-802ac1f8b3be",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.045,
        "w": 0.45,
        "x": 0.068,
        "y": 0.045
      },
      "kind": "title",
      "text": "Highlights and Upcoming Milestones",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d26e261c-eb61-4ebb-8fc8-b9a4af0e86bd",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}